Select to order medicines [Delhi/NCR /Bangalore /Chennai /Bhubaneswar /Mumbai]
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
Studies in breastfeeding mothers have demonstrated that there is significant and documented risk to the infant based on human experience, or it is a medication that has a high risk of causing significant damage to an infant. The risk of using the drug in breastfeeding women clearly outweighs any possible benefit from breastfeeding. The drug is contraindicated in women who are breastfeeding an infant.
Typical usage: Primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia, homozygous familial hypercholesterolaemia or combined hyperlipidaemia.
Side Effects: Flatulence, diarrhoea, nausea, vomiting, anorexia, xerostomia, angioedema, myalgia, rash, pruritus, alopecia, allergy, infection, chest pain.
Drug Interaction: Atorvastatin is known to interact with other drugs like alvimopan, atazanavir, boceprevir, carbamazepine, clarithromycin, cyclosporine, dronedarone, erythromycin, etravirine, ketoconazole, nefazodone. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Mechanism Of Action: Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.
Showing 5 of 221
Showing 5 of 221